Life Extension Super Ubiquinol CoQ10 100 mg with PrimaVie Shilajit Review

PrimaVie is the patent-grade standardised form of shilajit — a Himalayan mineral-rich resin used in Ayurveda. We have to correct ourselves here: we previously cited a head-to-head pharmacokinetic study showing ~29-39% higher peak plasma CoQ10 with the shilajit carrier. That study does not exist. Searches of Europe PMC for shilajit combined with coenzyme Q10, ubiquinol or PrimaVie return no pharmacokinetic trial at all, and the id we had attached belonged to a paper about small-intestinal bacterial overgrowth. The absorption-carrier figure traces to Natreon's own marketing material, not to peer-reviewed data. The proposed mechanism is dual: (1) shilajit's fulvic acid compounds appear to act as electron-shuttle co-factors that stabilise the reduced (ubiquinol) form during intestinal absorption, and (2) the mineral content (iron, magnesium, zinc) may support the CoQ10 biosynthesis pathway downstream. Both mechanisms are plausible on paper and neither has been measured in a human CoQ10 trial. So the honest framing of the price gap to Jarrow ($32.81 against $27.05 for 60 softgels on Oct 11, 2026) is that it buys Life Extension's QC chain and brand pedigree, not a demonstrated absorption gain.

Depends on your goal and your baseline. For under-50 buyers running the 100 mg/day longevity baseline, the answer is usually no — Jarrow's MCT carrier-oil softgel already closes most of the fasted-absorption gap, and the marginal PrimaVie gain is small. For 50+ buyers, statin users with significant myalgia, or anyone running a deliberate longevity-stack protocol where every percentage point of plasma Q10 counts, the honest answer is now no. The 29-39% absorption gain we used to cite for the shilajit carrier came from a study that does not exist; the carrier is a manufacturer claim with no published trial behind it, so it cannot justify the premium on its own. Life Extension's broader QC pedigree (40+ years, longevity-research focus, in-house labs) also matters for the buyer whose protocol is anchored to specific brand recommendations. Honest framing: this is the premium tier, justified for the specific buyer who values the upgrade.

It's a legitimate concern with generic shilajit but largely mitigated by PrimaVie's licensing. Raw shilajit from undisclosed Himalayan sources has had documented heavy-metal contamination (lead, mercury, arsenic) — sometimes at concerning levels. PrimaVie is a patent-grade standardised form produced by Natreon under a controlled supply chain with published heavy-metal testing per batch. Life Extension layers their own QC on top. The combination is safe at the dose ranges used in this product (100 mg/day). If you're buying generic 'shilajit' as a standalone supplement, the contamination concern is real and you should require published COA testing. In a PrimaVie-licensed product from Life Extension, the chain-of-custody is the strongest available in the consumer category.

Life Extension is the longevity-research-focused brand in consumer supplements — 40+ years of operation, in-house clinical research arm, and an editorial publication (Life Extension Magazine) that frames every product through a specific longevity-protocol lens. The pricing premium across the line buys: (1) higher-grade raw materials (Kaneka, PrimaVie, patent-standardised extracts as defaults), (2) tighter QC discipline than the household-brand tier, (3) the longevity-stack curation work that maps individual products to specific protocols. For buyers who are already running a Life Extension multivitamin, fish oil, and other staples, the brand consistency adds value. For one-off buyers looking at just CoQ10, the premium can feel disproportionate — that's why Jarrow (#1) often makes more sense if you're not committed to the broader Life Extension ecosystem.

Yes, and more than ever. CoQ10 is lipid-soluble, period, and the fat-with-the-dose effect is the one absorption lever here with real data behind it. Best practice: take 1 softgel with dinner (any meal containing 10g+ fat — eggs, avocado, olive oil, fatty fish, nuts). Two things in this bottle are supported by published work — the ubiquinol form and taking it with fat. The shilajit carrier is not. Skipping the fat-meal step throws away the most actionable lever in your protocol — don't pay for a premium bottle and then take it fasted with coffee.

It's a reasonable starting dose; for established statin myalgia you'll likely want 2 softgels/day. The Banach 2015 meta-analysis (PMID 25440725) found significant statin-myopathy improvement at 100-200 mg/day ubiquinol, with the 200 mg/day arm showing the more robust effect. Life Extension at 2 softgels/day = 200 mg ubiquinol + 200 mg PrimaVie shilajit — that's the active dose, and it turns the 60-softgel bottle into a 1-month supply: $32.81 on Oct 11, 2026. Jarrow delivers the same 200 mg of the same licensed Kaneka QH molecule for $27.05 a month, and there is no published evidence that the shilajit carrier makes Life Extension's version absorb better. At the statin dose the cheaper bottle is simply the better buy.

Life Extension sells two formulations under similar names — make sure you're buying the right one. The PrimaVie shilajit version (this product) ships Kaneka QH + PrimaVie shilajit at 100 mg/100 mg per softgel. The d-limonene version ships Kaneka QH + d-limonene (citrus extract) at 100 mg per softgel — the d-limonene serves a different absorption mechanism via gut-wall fluidisation rather than the shilajit's electron-shuttle co-factor approach. We used to say the shilajit version had the stronger published bioavailability data, citing Keller 2014. That study does not exist. Neither carrier has a published head-to-head against plain Kaneka QH, so choose on price and availability, not on an absorption claim — and there is no reason to stack both.

1. [1] Retracted by us — the PrimaVie + ubiquinol PK study does not exist — Withdrawn: no published pharmacokinetic study pairs shilajit with CoQ10. This slot used to carry a head-to-head pharmacokinetic comparison of Kaneka ubiquinol with and without the PrimaVie shilajit carrier, credited to named authors in a named journal, with a PMID. None of it holds up: the id belonged to a paper on small-intestinal bacterial overgrowth, and searches of Europe PMC for shilajit against coenzyme Q10, ubiquinol or PrimaVie return no pharmacokinetic trial in any journal. We are leaving the entry visible rather than deleting it, because a claim we printed for months deserves a correction our readers can see.
2. [2] Hosoe 2007 (Kaneka pharmacokinetics) PMID 16919858 — Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers. Pharmacokinetic study of Kaneka ubiquinol in healthy adults — established the dose-response curve and bioavailability advantage of the reduced form. The foundational PK paper for the Kaneka QH that Life Extension ships as the ubiquinol base of this formulation.
3. [3] Zhang 2018 (ubiquinol vs ubiquinone) PMID 30302465 — Ubiquinol is superior to ubiquinone to enhance Coenzyme Q10 status in older men. Head-to-head trial of ubiquinol vs ubiquinone in older men showing significantly higher plasma CoQ10 in the ubiquinol arm at equivalent oral doses. Confirms the 2-4× bioavailability advantage of the reduced form in adults 40+ — the primary justification for Life Extension's ubiquinol form choice.
4. [4] Mortensen 2014 (Q-SYMBIO) PMID 25282031 — The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. 420 chronic heart failure patients randomised to 3×100 mg/day Kaneka CoQ10 vs placebo for 2 years. CoQ10 group showed 43% reduction in major adverse cardiovascular events and significant reduction in cardiovascular mortality. The pivotal outcome trial that anchors the Life Extension CHF-protocol dose.
5. [5] Banach 2015 (statin myopathy meta) PMID 25440725 — Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Meta-analysis of 12 RCTs (n=575) on CoQ10 supplementation in statin users with myopathy. Pooled effect showed significant reduction in statin-induced muscle pain, weakness, cramps, and tiredness — the 200 mg/day dose protocol that justifies Life Extension's 2-softgel statin-support recommendation.
6. [6] Hernández-Camacho 2018 (review) PMID 29459830 — Coenzyme Q10 supplementation in aging and disease. Comprehensive review of CoQ10 in aging, cardiovascular disease, neurodegeneration, and statin-induced complications. Establishes the age-related decline curve (~50% drop by age 60 in heart and skeletal muscle) and the rationale for high-bioavailability ubiquinol supplementation in 50+ adults — the population Life Extension's premium positioning targets.